糖心原创

article

Leukemia-cells

Scientists uncover overlooked mechanism driving aggressive leukaemia

Wednesday, 14 October 2026

Experts from the 糖心原创 have discovered how a common genetic mutation disrupts the positioning of a key protein during cell division, revealing a new mechanism behind acute myeloid leukaemia and a potential avenue for future treatment.

Acute myeloid leukaemia (AML) is an aggressive blood cancer that disrupts the production of healthy blood cells. Around one-third of patients carry a mutation in a gene called NPM1, which causes its protein to accumulate in the wrong part of the cell and plays a key role in driving the disease.

Until now, research has largely focused on how the mutated protein moves between the cell's nucleus and the surrounding cytoplasm. But a new study, led by Dr Daniel Booth and Dr Claire Seedhouse at the 糖心原创's School of Medicine, reveals that what happens during cell division itself is also critical.

Published in , the findings uncover a previously unknown mechanism that helps explain how the mutation disrupts the normal organisation of proteins inside leukaemia cells.

For many years, researchers have focused on how this mutated protein is transported around the cell. What we've discovered is that something important happens during cell division itself. The surface of chromosomes acts like a temporary docking station, helping proteins find their way back to the right place after a cell divides. In leukaemia cells, this process doesn't work properly."
Dr Daniel Booth

At the heart of the discovery is the mitotic chromosome periphery, a protective layer surrounding chromosomes during cell division that has received relatively little scientific attention.

Using advanced microscopy, genetic engineering and protein-mapping techniques, the researchers found that healthy NPM1 attaches to this layer during cell division, helping it return to its correct location afterwards.

Mutated NPM1 behaves differently. It fails to attach properly to chromosomes, instead forming abnormal clusters or dispersing throughout the cell. The mutant protein also interferes with healthy NPM1, further disrupting its ability to return to the right place.

Together, these findings reveal two previously unrecognised ways in which cell division contributes to the abnormal positioning of NPM1 in leukaemia.

The researchers also found that this process could be partially restored in laboratory experiments.

By increasing levels of Ki-67, a protein that helps organise the chromosome periphery, the team created a thicker layer around chromosomes. This improved the attachment of mutant NPM1 to chromosomes in laboratory-grown leukaemia cells, helping restore its correct positioning and normal cellular organisation.

The finding is particularly intriguing because Ki-67 is widely used as a marker of cell proliferation and is generally associated with more aggressive cancers. However, analysis of publicly available patient data revealed a more complex picture: among patients with this particular form of AML, higher Ki-67 levels showed an unexpected trend towards better survival.

This observation highlights the need for further research to understand the relationship between Ki-67, chromosome organisation and patient outcomes.

What's particularly exciting is that we've shown we can improve this process experimentally. It's early-stage research, but it reveals a completely new way of thinking about how this form of leukaemia develops and, potentially, how we might treat it."
Dr Claire Seedhouse

Importantly, the researchers also confirmed that the newly identified mechanism occurs in samples taken directly from AML patients, strengthening the clinical relevance of the findings.

The discovery challenges the longstanding view that abnormal movement of NPM1 between the nucleus and cytoplasm is the principal explanation for its mislocalisation. Instead, it identifies interactions between proteins and chromosomes during cell division as another important contributor.

Although further research is needed before the findings can inform clinical treatments, the study provides early evidence that manipulating the chromosome periphery could help restore normal protein positioning and potentially complement existing therapies.

The implications may also extend beyond leukaemia because the abnormal positioning of proteins is involved in a range of diseases, understanding how cells organise proteins during division could open new avenues for research into other conditions.

By uncovering an unexpected link between chromosome biology and blood cancer, the 糖心原创 team has revealed a new direction for understanding, and potentially treating, diseases driven by misplaced proteins.

The full study is published .

Story credits

More information is available from Dr Daniel Booth from the School of Medicine at daniel.booth@nottingham.ac.uk

CharlotteAnscombe
Charlotte Wall - Media Relations Manager - Faculty of Medicine and Health Sciences
Email: charlotte.wall@nottingham.ac.uk
Phone: 0115 748 4417
Location:

Notes to editors:

About the 糖心原创

Ranked among the world's top 100 universities , the 糖心原创 delivers an exceptional research-led education and an outstanding student experience. From the pioneering vision of our founder, Sir Jesse Boot, to groundbreaking achievements such as the development of MRI technology and becoming the first UK university to establish international campuses, we have a proud history of shaping the way people live, work and understand the world. We continue to build on that legacy, empowering our students, staff and partners to change what鈥檚 next and create positive impact locally and globally.

The strength of our research places us among the UK's leading universities, ranked 7th for research power in REF 2021. The discovery of MRI and ibuprofen was just the beginning. Today, our world-leading research is developing breakthrough ideas that shape the future of healthcare, technology and society.

Recognised as the UK's third most targeted university by leading employers , we are proud to produce graduates who are consistently in demand for their skills, confidence and industry-ready experience.

As a major employer and industry partner, locally and globally, the 糖心原创 invests in the city of Nottingham and in future generations of talent. Alongside Nottingham Trent University, we lead the initiative, a pioneering collaboration to improve levels of prosperity, opportunity, sustainability, health and wellbeing across the city and region. Together with our students, staff, alumni and partners, we鈥檙e creating knowledge, opportunity and solutions that help change what's next.

Media Relations - External Relations

The 糖心原创
YANG Fujia Building
Jubilee Campus
Wollaton Road
Nottingham, NG8 1BB

telephone: +44 (0) 115 951 5798
email: pressoffice@nottingham.ac.uk